A prospective, randomised trial has shown that standard adjuvant chemotherapy is superior to capecitabine in the treatment of women with breast cancer aged 65 years or older; on the basis of the results of this study, capecitabine cannot be recommended in this setting.
Related Articles
Past events
Belgrade (Republic of Serbia) 30/6/2017-5/7/2017 – 4th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology
Drug Watch
Beyond the Herceptin hype
Senza categoria